Luke Thomas Power - 11 Dec 2025 Form 4 Insider Report for Caris Life Sciences, Inc.

Role
Senior Vice President, Chief Financial Officer, and Chief Accounting Officer
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Issuer symbol
CAI on Nasdaq
Transactions as of
11 Dec 2025
Net transactions value
-$1,502,571
Form type
4
Filing time
12 Dec 2025, 19:39:15 UTC
Previous filing
23 Jun 2025
Next filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Power Luke Thomas Senior Vice President, Chief Financial Officer, and Chief Accounting Officer C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 12 Dec 2025 0002072013

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAI Common Stock Options Exercise $60,390 +24,750 +25% $2.44 124,321 11 Dec 2025 Direct F1
transaction CAI Common Stock Options Exercise $91,500 +37,500 +30% $2.44 161,821 11 Dec 2025 Direct F1
transaction CAI Common Stock Sale $1,616,444 -60,850 -38% $26.56 100,971 11 Dec 2025 Direct F1, F2
transaction CAI Common Stock Sale $38,018 -1,400 -1.4% $27.16 99,571 11 Dec 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAI Stock Option Options Exercise $0 -24,750 -100% $0.000000 0 11 Dec 2025 Common Stock 24,750 $2.44 Direct F1, F4
transaction CAI Stock Option Options Exercise $0 -37,500 -100% $0.000000 0 11 Dec 2025 Common Stock 37,500 $2.44 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option is fully vested and exercisable.

Remarks:

Senior Vice President, Chief Financial Officer, and Chief Accounting Officer